Matches in Nanopublications for { <http://bio2rdf.org/drugbank:DB05708> ?p ?o ?g. }
Showing items 1 to 15 of
15
with 100 items per page.
- drugbank:DB05708 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05708 label "GTS-21 [drugbank:DB05708]" assertion.
- drugbank:DB05708 seeAlso DB05708 assertion.
- drugbank:DB05708 description "GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006. GTS-21 has been studied in multiple Phase I studies in healthy volunteers and one Phase I/II study in schizophrenic patients. In all studies, the compound was well tolerated. In a Phase I multi-dose, double-blind, placebo controlled study in healthy adults, GTS-21 also demonstrated cognitive enhancement across all doses, with a statistically significant improvement in attention related and memory related tasks (Kitagawa, et al. Neuropsychopharmacology (2003), 28, 542-551)." assertion.
- drugbank:DB05708 identifier "drugbank:DB05708" assertion.
- drugbank:DB05708 title "GTS-21" assertion.
- drugbank:DB05708 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:43031369 assertion.
- drugbank:DB05708 drugbank_vocabulary:x-pubchemcompound pubchem.compound:6438361 assertion.
- drugbank:DB05708 drugbank_vocabulary:x-chemspider chemspider:4942844 assertion.
- drugbank:DB05708 drugbank_vocabulary:x-cas cas:156223-05-1 assertion.
- drugbank:DB05708 drugbank_vocabulary:drugbank-id "DB05708" assertion.
- drugbank:DB05708 bio2rdf_vocabulary:x-identifiers.org DB05708 assertion.
- drugbank:DB05708 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05708" assertion.
- drugbank:DB05708 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05708 bio2rdf_vocabulary:identifier "DB05708" assertion.